secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001438533-26-000005
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA extends FILSPARI FSGS sNDA PDUFA to April 13, 2026; cites Major Amendment
-----------------------------------------------------------------------------

- FDA extended PDUFA target action date to April 13, 2026, after determining supplemental NDA responses constitute a Major Amendment.
- No safety or manufacturing concerns raised; FDA requested additional characterization of FILSPARI's clinical benefit in FSGS.
- If approved, FILSPARI would be the first FDA-approved pharmacologic therapy for focal segmental glomerulosclerosis (FSGS).
- Phase 3 DUPLEX study missed primary eGFR slope endpoint but showed proteinuria reduction and lower end-stage kidney disease rate vs irbesartan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000005/0001438533-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000005/tvtx-20260113.htm
  HTML page:      https://secwatch.observer/filing/0001438533-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer